CN117402852A - 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 - Google Patents

对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 Download PDF

Info

Publication number
CN117402852A
CN117402852A CN202311305067.1A CN202311305067A CN117402852A CN 117402852 A CN117402852 A CN 117402852A CN 202311305067 A CN202311305067 A CN 202311305067A CN 117402852 A CN117402852 A CN 117402852A
Authority
CN
China
Prior art keywords
seq
hbv
meganuclease
engineered
engineered meganuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311305067.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·扬茨
J·J·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Biosciences Inc
Original Assignee
Precision Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biosciences Inc filed Critical Precision Biosciences Inc
Publication of CN117402852A publication Critical patent/CN117402852A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202311305067.1A 2016-10-14 2017-10-13 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 Pending CN117402852A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662408356P 2016-10-14 2016-10-14
US62/408,356 2016-10-14
US201762452506P 2017-01-31 2017-01-31
US62/452,506 2017-01-31
US201762527159P 2017-06-30 2017-06-30
US201762527196P 2017-06-30 2017-06-30
US62/527,196 2017-06-30
US62/527,159 2017-06-30
PCT/US2017/056638 WO2018071849A2 (en) 2016-10-14 2017-10-13 Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
CN201780074346.8A CN110023495A (zh) 2016-10-14 2017-10-13 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780074346.8A Division CN110023495A (zh) 2016-10-14 2017-10-13 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶

Publications (1)

Publication Number Publication Date
CN117402852A true CN117402852A (zh) 2024-01-16

Family

ID=60480360

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780074346.8A Pending CN110023495A (zh) 2016-10-14 2017-10-13 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
CN202311305067.1A Pending CN117402852A (zh) 2016-10-14 2017-10-13 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780074346.8A Pending CN110023495A (zh) 2016-10-14 2017-10-13 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶

Country Status (21)

Country Link
US (6) US10662416B2 (enExample)
EP (2) EP4234691A3 (enExample)
JP (5) JP6811857B2 (enExample)
KR (4) KR20230010826A (enExample)
CN (2) CN110023495A (enExample)
AU (2) AU2017342536A1 (enExample)
BR (1) BR112019007450A2 (enExample)
CA (1) CA3040143A1 (enExample)
CL (1) CL2019000993A1 (enExample)
CO (1) CO2019003675A2 (enExample)
CR (1) CR20190181A (enExample)
DK (1) DK3526323T5 (enExample)
DO (1) DOP2019000097A (enExample)
FI (1) FI3526323T3 (enExample)
IL (3) IL265921B2 (enExample)
MA (1) MA46535A (enExample)
MX (2) MX2019004349A (enExample)
PE (1) PE20191353A1 (enExample)
PH (1) PH12019500788A1 (enExample)
SG (2) SG11201903042VA (enExample)
WO (1) WO2018071849A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234691A3 (en) 2016-10-14 2023-10-18 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US11142750B2 (en) * 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CA3137975A1 (en) 2019-05-07 2020-11-12 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4244342A1 (en) * 2020-11-12 2023-09-20 Precision BioSciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
WO2025096916A1 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Multi-site editing in living cells
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
JPH07502653A (ja) 1991-12-23 1995-03-23 カイロン　コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｈｂｖ増幅プローブ
EP1288296A3 (en) * 1992-05-11 2003-03-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting HBV viral replication
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
CN1204248C (zh) * 2002-02-05 2005-06-01 中国人民解放军第四军医大学 治疗乙肝病毒感染的靶向核糖核酸酶的制备工艺
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
HUE043492T2 (hu) 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
DK2628794T3 (en) 2005-10-18 2016-08-15 Prec Biosciences RATIONALE CONSTRUCTED MECHANUCLEAS WITH CHANGED SEQUENCE SPECIFICITY AND DNA BINDING EFFICIENCY
JP4235837B2 (ja) 2006-04-04 2009-03-11 セイコーエプソン株式会社 粒状性の予測、プロファイルの作成および印刷装置
CA2656427C (en) 2006-07-07 2014-12-09 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2009001159A1 (en) 2007-06-25 2008-12-31 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
WO2008103380A2 (en) * 2007-02-21 2008-08-28 Fox Chase Cancer Center Hepatitis b virus compositions and methods of use
TWI434849B (zh) 2007-06-29 2014-04-21 Gilead Sciences Inc 類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑
ES2732735T3 (es) 2007-10-31 2019-11-25 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
MX2011000235A (es) 2008-07-08 2011-02-23 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa.
ES2438496T3 (es) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
WO2010136841A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
WO2010136981A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
CN102753542B (zh) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 作为t0ll样受体调节剂的取代的苯并氮杂*
RU2016108987A (ru) 2009-08-18 2018-11-26 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
EA020488B1 (ru) 2009-10-22 2014-11-28 Джилид Сайэнс, Инк. Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
NZ608673A (en) 2010-10-01 2015-04-24 Univ Pennsylvania Therapeutic use of a tlr agonist and combination therapy
JP6092107B2 (ja) 2010-10-01 2017-03-08 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アレルギー性疾患の治療方法
AR084217A1 (es) 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
HRP20170401T1 (hr) 2011-01-12 2017-05-19 Ventirx Pharmaceuticals, Inc. SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
EP3207930A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
AU2012258220B2 (en) 2011-05-18 2017-01-19 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
DK2714936T3 (en) 2011-06-01 2019-03-25 Prec Biosciences Inc METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
TWI659040B (zh) * 2011-06-30 2019-05-11 美商艾羅海德製藥公司 用於抑制ｂ型肝炎病毒基因表現之組合物及方法
US20140120106A1 (en) * 2011-07-06 2014-05-01 Yale University Stimulation of Arterial Collateral Growth and Lymphogenesis
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
EP2831108A1 (en) 2012-03-29 2015-02-04 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
JP6141402B2 (ja) 2012-03-31 2017-06-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の治療および予防のための新規４−メチル−ジヒドロピリミジン
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
MX2014014766A (es) 2012-06-08 2015-05-11 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae.
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
JP6209600B2 (ja) 2012-06-08 2017-10-04 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスの大環状阻害剤
AU2013301450B2 (en) 2012-08-10 2018-01-18 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
KR102148237B1 (ko) 2012-08-28 2020-08-27 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 융합 바이사이클릭 설파모일 유도체 및 b형 간염 치료제로서의 그 용도
EP2892893B2 (en) 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HRP20170358T1 (hr) 2012-10-02 2017-04-21 Gilead Sciences, Inc. Inhibitori histonskih demetilaza
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
PL2934145T3 (pl) 2012-12-19 2018-04-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy histonowej
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
ES2670864T3 (es) 2013-02-27 2018-06-01 Gilead Sciences, Inc. Inhibidores de histonas desmetilasas
PT2961732T (pt) 2013-02-28 2017-06-26 Janssen Sciences Ireland Uc Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
US9133166B2 (en) 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
PL2970211T3 (pl) 2013-03-15 2018-01-31 Quanticel Pharmaceuticals Inc Inhibitory demetylazy histonowej
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
EA201592126A1 (ru) 2013-05-17 2016-05-31 Ф. Хоффманн-Ля Рош Аг 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CA2909742C (en) 2013-05-17 2020-08-04 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
AU2014298540B2 (en) 2013-07-30 2018-08-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
CA2920377A1 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
PL3041468T3 (pl) 2013-09-06 2018-12-31 Aurigene Discovery Technologies Limited Pierścieniowe związki peptydomimetyczne jako immunomodulatory
CU24345B1 (es) 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
EA030155B1 (ru) 2013-09-06 2018-06-29 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
PT3043865T (pt) 2013-09-11 2021-01-14 Univ Claude Bernard Lyon Métodos e composições farmacêuticas para o tratamento da infeção por vírus da hepatite b
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
NZ717629A (en) 2013-10-23 2021-12-24 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6490686B2 (ja) 2013-11-14 2019-03-27 ノヴィラ・セラピューティクス・インコーポレイテッド アゼパン誘導体及びｂ型肝炎感染の治療方法
CA2932479A1 (en) * 2013-12-12 2015-06-18 The Rockefeller University Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
EP3080124A1 (en) 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
WO2015095780A1 (en) 2013-12-20 2015-06-25 The University Of Kansas Toll-like receptor 8 agonists
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN105899508B (zh) 2014-01-30 2017-07-04 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物
EP3102237B1 (en) 2014-02-04 2020-12-02 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
KR20160119867A (ko) 2014-03-05 2016-10-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PL3134402T3 (pl) 2014-04-22 2020-11-02 F.Hoffmann-La Roche Ag Związki 4-amino-imidazochinolinowe
CR20160512A (es) 2014-05-01 2016-12-21 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7
KR20160144399A (ko) 2014-05-01 2016-12-16 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
KR20160148715A (ko) 2014-05-13 2016-12-26 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
SG11201609770TA (en) 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer
CN106574256A (zh) 2014-05-30 2017-04-19 斯坦福大学托管董事会 用于潜伏病毒感染的递送治疗的组合物和方法
WO2015188085A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016019232A1 (en) 2014-08-01 2016-02-04 John Vasilakos Methods and therapeutic combinations for treating tumors
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
WO2016029077A1 (en) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
US9884866B2 (en) 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
BR112017003718B1 (pt) 2014-09-11 2023-04-11 Bristol-Myers Squibb Company Inibidores macrocíclicos das interações de proteína/proteína de pd- 1/pd-l1 e cd80(b7-1)/pd-l1
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
CN107001386A (zh) 2014-10-11 2017-08-01 豪夫迈·罗氏有限公司 用于治疗感染性疾病的化合物
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
KR102557560B1 (ko) 2014-12-08 2023-07-20 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물
JP6644792B2 (ja) 2014-12-18 2020-02-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンザゼピンスルホンアミド化合物
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
WO2016109663A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CN107208102B (zh) 2015-01-27 2021-07-06 豪夫迈·罗氏有限公司 重组hbv cccdna、其产生方法及其用途
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
CN107207505B (zh) 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
RS58356B1 (sr) 2015-03-06 2019-03-29 Hoffmann La Roche Jedinjenja benzazepin dikarboksamida
KR102708045B1 (ko) 2015-03-10 2024-09-23 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
CN107427476A (zh) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物
BR112017019306A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
EP3267998A4 (en) 2015-03-10 2018-12-19 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
EP3283472B1 (en) 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Hepatitis b viral assembly effectors
JP6462155B2 (ja) 2015-05-04 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
EP4001283A1 (en) 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
GB201511477D0 (en) 2015-06-30 2015-08-12 Redx Pharma Plc Antiviral compounds
EP3317289B1 (en) 2015-06-30 2021-10-27 F. Hoffmann-La Roche AG Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
WO2017013046A1 (en) 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
CN107820496B (zh) 2015-07-27 2020-11-03 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的四环4-氧代-吡啶-3-甲酸衍生物
CN107835813B (zh) 2015-07-28 2020-04-24 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的6,7-二氢吡啶并[2,1-a]酞嗪-2-酮类化合物
KR20180030911A (ko) 2015-07-29 2018-03-26 노파르티스 아게 Pd-1 길항제와 egfr 억제제의 조합물
MX386992B (es) 2015-08-10 2025-03-19 Merck Sharp & Dohme Llc Compuestos antivirales de fosfodiamida de éster de beta-aminoácido.
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
US11130736B2 (en) 2015-08-21 2021-09-28 University Of Kansas Human TLR8-selective agonists
WO2017038909A1 (en) 2015-08-28 2017-03-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2017040233A1 (en) 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017047769A1 (ja) 2015-09-17 2017-03-23 国立大学法人富山大学 トール様受容体７またはトール様受容体９の活性化阻害剤
WO2017046112A1 (en) 2015-09-17 2017-03-23 F. Hoffmann-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
JP6723254B2 (ja) 2015-10-05 2020-07-15 富士フイルム富山化学株式会社 抗ｂ型肝炎ウイルス剤
JP6769976B2 (ja) 2015-10-07 2020-10-14 大日本住友製薬株式会社 ピリミジン化合物
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201726700A (zh) 2015-10-28 2017-08-01 艾杜諾生物科技公司 用於活化「干擾素基因刺激子」依賴性訊號之組合物及方法
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
JP2018532756A (ja) 2015-11-04 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
JP6524355B2 (ja) 2015-11-05 2019-06-05 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｔｌｒ７アゴニストとしての７−（チアゾール−５−イル）ピロロピリミジン化合物
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
NZ738202A (en) 2015-12-03 2019-07-26 Glaxosmithkline Ip Dev Ltd Cyclic purine dinucleotides as modulators of sting
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3889145B1 (en) 2015-12-17 2024-02-21 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
DK3394033T3 (da) 2015-12-22 2021-01-04 Incyte Corp Heterocykliske forbindelser som immunmodulatorer
WO2017112859A1 (en) * 2015-12-23 2017-06-29 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
WO2017140821A1 (en) 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
US10662177B2 (en) 2016-03-21 2020-05-26 Council Of Scientific & Industrial Research Blocking toll-like receptor 9 signaling with small molecule antagonist
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
KR20180134395A (ko) 2016-04-19 2018-12-18 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3452583B1 (en) * 2016-05-03 2021-10-27 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia a
SG11201809859VA (en) 2016-05-06 2018-12-28 Shanghai De Novo Pharmatech Co Ltd Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
CN109153648B (zh) 2016-05-23 2022-07-22 豪夫迈·罗氏有限公司 具有叔酰胺官能团的苯并氮杂卓二甲酰胺化合物
CN109311854B (zh) 2016-05-23 2021-08-10 豪夫迈·罗氏有限公司 具有仲酰胺官能团的苯并氮杂卓二甲酰胺化合物
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CN109311860B (zh) 2016-05-26 2022-04-08 豪夫迈·罗氏有限公司 用于治疗或预防乙型肝炎病毒疾病的呫吨酮衍生物
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
EP3468561A4 (en) 2016-06-10 2019-12-04 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
CN109311851B (zh) 2016-06-12 2021-08-10 豪夫迈·罗氏有限公司 二氢嘧啶基苯并氮杂䓬甲酰胺化合物
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017219931A1 (zh) 2016-06-22 2017-12-28 四川科伦博泰生物医药股份有限公司 二氢蝶啶酮类衍生物、其制备方法及其用途
ES2817426T3 (es) 2016-06-29 2021-04-07 Novira Therapeutics Inc Derivados de oxadiazepinona y su uso en el tratamiento de infecciones por hepatitis B
CN109415367B (zh) 2016-06-29 2021-04-16 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的二氢吡咯并嘧啶类化合物
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109311880B (zh) 2016-06-29 2021-09-03 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶类化合物
EP3478683B1 (en) 2016-06-29 2021-07-21 Novira Therapeutics Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
KR102468272B1 (ko) 2016-06-30 2022-11-18 삼성전자주식회사 음향 출력 장치 및 그 제어 방법
EP3478688A1 (en) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
ES2895066T3 (es) 2016-07-08 2022-02-17 Bristol Myers Squibb Co Derivados de 1,3-dihidroxi-fenilo útiles como inmunomoduladores
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CN109476668B (zh) 2016-07-14 2022-03-22 豪夫迈·罗氏有限公司 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物
CN109415368B (zh) 2016-07-14 2021-04-30 豪夫迈·罗氏有限公司 用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物
WO2018011100A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
CN110156774A (zh) 2016-07-29 2019-08-23 新波制药有限公司 用于治疗hbv感染的新颖治疗剂
WO2018019297A1 (zh) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
EP3493804A1 (en) 2016-08-03 2019-06-12 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
WO2018031434A1 (en) 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
CN109689059A (zh) 2016-08-24 2019-04-26 豪夫迈·罗氏有限公司 Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法
JP7010286B2 (ja) 2016-08-26 2022-01-26 スリーエム イノベイティブ プロパティズ カンパニー グアニジノ基で置換された縮合［１，２］イミダゾ［４，５－ｃ］環状化合物
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
WO2018043747A1 (ja) 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
EP3510036B1 (en) 2016-09-07 2021-07-21 GlaxoSmithKline Biologicals SA Imidazoquinoline derivatives and their use in therapy
WO2018045911A1 (zh) 2016-09-09 2018-03-15 浙江海正药业股份有限公司 二氢嘧啶类化合物及其制备方法和用途
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
MY194813A (en) 2016-09-09 2022-12-16 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
GEP20217285B (en) 2016-10-04 2021-08-10 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
EP4234691A3 (en) 2016-10-14 2023-10-18 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
EA201990997A1 (ru) 2016-10-20 2019-08-30 Ориджин Дискавери Текнолоджиз Лимитед Двойные ингибиторы vista и путей pd-1
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
WO2018078149A1 (en) 2016-10-31 2018-05-03 F. Hoffmann-La Roche Ag Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
ES2910832T3 (es) 2016-11-07 2022-05-13 Bristol Myers Squibb Co Inmunomoduladores
EP3538513A1 (en) 2016-11-11 2019-09-18 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
WO2018086593A1 (zh) 2016-11-11 2018-05-17 礼沃（上海）医药科技有限公司 含氮杂环化合物、制备方法、中间体、药物组合物和应用
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
RU2748833C2 (ru) 2016-11-28 2021-05-31 Цзянсу Хэнжуй Медсин Ко., Лтд. Производное пиразоло-гетероарила, способ его получения и медицинское применение
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
ES2891528T3 (es) 2016-12-20 2022-01-28 Bristol Myers Squibb Co Compuestos útiles como inmunomoduladores
RU2019122602A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
US10519159B2 (en) 2016-12-22 2019-12-31 Merck Sharp & Dohme Corp. Antiviral aliphatic ester prodrugs of tenofovir
JP2020504734A (ja) 2016-12-22 2020-02-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ウイルス性ベンジル−アミンホスホジアミド化合物
JPWO2018199338A1 (ja) 2017-04-27 2020-03-12 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

Also Published As

Publication number Publication date
MX2024001134A (es) 2024-02-27
PE20191353A1 (es) 2019-10-01
MA46535A (fr) 2019-08-21
KR20240123417A (ko) 2024-08-13
US20200239864A1 (en) 2020-07-30
DK3526323T3 (da) 2023-06-26
EP3526323A2 (en) 2019-08-21
CN110023495A (zh) 2019-07-16
DK3526323T5 (da) 2024-09-02
BR112019007450A2 (pt) 2020-07-07
DOP2019000097A (es) 2019-07-31
CO2019003675A2 (es) 2019-04-30
US11274285B2 (en) 2022-03-15
US10851358B2 (en) 2020-12-01
JP2021061841A (ja) 2021-04-22
KR20210118240A (ko) 2021-09-29
MX2019004349A (es) 2019-09-26
KR20230010826A (ko) 2023-01-19
FI3526323T3 (fi) 2023-06-06
US10662416B2 (en) 2020-05-26
SG11201903042VA (en) 2019-05-30
AU2023263542A1 (en) 2023-11-30
IL317537A (en) 2025-02-01
EP4234691A3 (en) 2023-10-18
EP3526323B1 (en) 2023-03-29
JP6811857B2 (ja) 2021-01-13
WO2018071849A2 (en) 2018-04-19
PH12019500788A1 (en) 2019-11-11
IL308894A (en) 2024-01-01
US20190284543A1 (en) 2019-09-19
US20250154486A1 (en) 2025-05-15
IL265921A (en) 2019-06-30
SG10201914029RA (en) 2020-03-30
US20240271111A1 (en) 2024-08-15
KR102305215B1 (ko) 2021-09-28
AU2017342536A1 (en) 2019-05-02
EP4234691A2 (en) 2023-08-30
JP6919049B2 (ja) 2021-08-11
US20220243187A1 (en) 2022-08-04
JP2023153824A (ja) 2023-10-18
JP2025138637A (ja) 2025-09-25
CA3040143A1 (en) 2018-04-19
IL265921B1 (en) 2024-01-01
CR20190181A (es) 2019-08-21
JP2021180665A (ja) 2021-11-25
KR20190064628A (ko) 2019-06-10
CL2019000993A1 (es) 2019-08-30
IL265921B2 (en) 2024-05-01
US20210180038A1 (en) 2021-06-17
JP2019530462A (ja) 2019-10-24
WO2018071849A3 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
US20250154486A1 (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US11788077B2 (en) Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN110769845B (zh) 对pcsk9基因中的识别序列具有特异性的工程化大范围核酸酶
CN120843482A (zh) 用于识别序列的工程化大范围核酸酶的优化
HK40012293A (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
EA042452B1 (ru) Сконструированные мегануклеазы, специфичные к последовательностям распознавания в геноме вируса гепатита b
HK40006308A (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
HK40006308B (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination